In ovarian cancer, inhibition of EMT can effectively eliminate cisplatin resistance.43 Byers et al.40 revealed a correlation between a 76-gene mesenchymal signature and non-small-cell lung cancer (NSCLC) resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) inhibitors. Here, AKT1 is linked to ovarian cancer.